https://www.selleckchem.com/pr....oducts/Gefitinib.htm
51; 95%CI 1.25-1.83; P 0.001) and 24 months (RR 1.51; 95%CI 1.30-1.77; P 0.001). Patients who received DEB had reduced the risk of restenosis after 6 (RR 0.47; 95%CI 0.33-0.67; P 0.001) and 12 months (RR 0.55; 95%CI 0.35-0.85; P = 0.008). DEB reduced the risk of major adverse events after 6 (RR 0.30; 95%CI 0.14-0.61; P = 0.001), 12 (RR 0.49; 95%CI 0.32-0.76; P = 0.001) and 24 months (RR 0.62; 95%CI 0.41-0.92; P = 0.018). DEB yielded additional benefits on MLD, LLL, primary patency, restenosis, TLR, and major adverse eve
Like
Comment
Share
